User menu

Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis

Bibliographic reference van der Hage, Jos A. ; Mieog, J. Sven D. ; de Vijver, Marc J. van ; de Velde, Cornelis J. H. van. Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. In: Breast Cancer Research, Vol. 9, no. 5 (2007)
Permanent URL
  1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, 10.1016/s0140-6736(05)66544-0
  2. Hankey BF, Miller B, Curtis R, Kosary C: Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr. 1994, 16: 7-14.
  3. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001, 19: 3817-3827.
  4. Elkhuizen PH, van Slooten HJ, Clahsen PC, Hermans J, van de Velde CJH, van den Broek LC, van de Vijver MJ: High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol. 2000, 18: 1075-1083.
  5. Aebi Stefan, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A, Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?, 10.1016/s0140-6736(00)02292-3
  6. van Dongen J. A., Long-Term Results of a Randomized Trial Comparing Breast-Conserving Therapy With Mastectomy: European Organization for Research and Treatment of Cancer 10801 Trial, 10.1093/jnci/92.14.1143
  7. van der Hage J.A, van de Velde C.J.H, Julien J.-P, Floiras J.-L, Delozier T, Vandervelden C, Duchateau L, Improved survival after one course of perioperative chemotherapy in early breast cancer patients, 10.1016/s0959-8049(01)00294-5
  8. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L: Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol. 2001, 19: 4224-4237.
  9. Bartelink Harry, Horiot Jean-Claude, Poortmans Philip, Struikmans Henk, Van den Bogaert Walter, Barillot Isabelle, Fourquet Alain, Borger Jacques, Jager Jos, Hoogenraad Willem, Collette Laurence, Pierart Marianne, Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation, 10.1056/nejmoa010874
  10. Bloom H J G, Richardson W W, Histological Grading and Prognosis in Breast Cancer, 10.1038/bjc.1957.43
  11. Bubendorf Lukas, Nocito Antonio, Moch Holger, Sauter Guido, Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughputin situ studies, 10.1002/path.893
  12. Hoos Axel, Urist Marshall J., Stojadinovic Alexander, Mastorides Stephen, Dudas Maria E., Leung Denis H.Y., Kuo David, Brennan Murray F., Lewis Jonathan J., Cordon-Cardo Carlos, Validation of Tissue Microarrays for Immunohistochemical Profiling of Cancer Specimens Using the Example of Human Fibroblastic Tumors, 10.1016/s0002-9440(10)64075-8
  13. Mueller-Holzner Elisabeth, Fink Vroni, Frede Thomas, Marth Christian, Immunohistochemical determination of her2 expression in breast cancer from core biopsy specimens: a reliable predictor of her2 status of the whole tumor, 10.1023/a:1012281221647
  14. Kallioniemi O.-P., Tissue microarray technology for high-throughput molecular profiling of cancer, 10.1093/hmg/10.7.657
  15. Kaplan E. L., Meier Paul, Nonparametric Estimation from Incomplete Observations, 10.1080/01621459.1958.10501452
  16. Cox DR: Regression models and life-tables. J R Stat Assoc [B]. 1972, 34: 187-220.
  17. Viale G, Gelber RD, Mastropasqua MG, Maiorano E, Aldrighetto S, Price KN, Castiglione-Gertsch M, Goldhirsch A: Chemo-endocrine effects of adjuvant therapies for postmenopausal node-negative breast cancer according to ER, PgR, and Her2 assessed centrally. Breast Cancer Res Treat. 2003, 82S: S16-S17.
  18. Albain K, Barlow W, O'Malley F, Siziopikou K, Yeh I-T, Ravdin P, Lew D, Farrar W, Burton G, Ketchel S, for the Breast Cancer Intergroup of North America, et al: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat. 2004, 88S: abstract 37
  19. Ring A E, Smith I E, Ashley S, Fulford L G, Lakhani S R, Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer, 10.1038/sj.bjc.6602235
  20. Colleoni M., Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment, 10.1158/1078-0432.ccr-04-0380
  21. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999, 17: 460-469.
  22. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials, 10.1016/s0140-6736(07)60778-8
  23. Jonat W., Pritchard K.I., Sainsbury R., Klijn J.G., Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient, 10.1007/s00432-006-0082-z
  24. Goldhirsch A., Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005, 10.1093/annonc/mdi326